

# HYPOPARATHYROIDISM EXPLAINED

## Hypoparathyroidism is an orphan disease

An orphan condition is defined as **life-threatening or chronically debilitating** and has a prevalence in the EU of **less than 5 in 10,000**<sup>1</sup>




Women are **3 times more likely** to be affected by hypoparathyroidism than men<sup>2-6</sup>



**In most cases**, patients with chronic hypoparathyroidism have had thyroid surgery (approximately 75% of cases)<sup>2,3,7</sup>


## THE PREVALENCE OF HYPOPARATHYROIDISM IS:



Treatment of hypoparathyroidism to date has focused on **maintaining serum calcium** with daily oral calcium and active vitamin D



ESE Guidelines recommend that treatment should aim to **maintain normal levels of minerals** and prevent symptoms of low calcium while optimizing quality of life<sup>9</sup>




Some patients with chronic hypoparathyroidism have **difficulty maintaining calcium levels** within the normal range and require high doses of calcium and vitamin D supplementation<sup>6</sup>

In those patients where there is **not sufficient control of serum and urine calcium levels**, additional treatments may be required to address the underlying condition<sup>9</sup>

# Hypoparathyroidism has a broad impact on patients' lives

**TYPICALLY HYPOPARATHYROIDISM PATIENTS EXPERIENCE SYMPTOMS SUCH AS:<sup>9,11</sup>**

**PATIENTS WITH CHRONIC HYPOPARATHYROIDISM CAN EXPERIENCE CO-MORBIDITIES SUCH AS:<sup>9</sup>**



In patients whose hypoparathyroidism is not adequately controlled, the effects of low calcium levels in the body may have a significant impact on well-being, ability to work and interact socially, and can lead to increased healthcare costs<sup>2,5,12</sup>

## Shire is committed to discovering breakthrough science in rare diseases where no therapy currently exists



Shire has committed to the development of an extensive programme of scientific and real life research in hypoparathyroidism, as well as long-term data generation including a patient registry and additional clinical studies



As a leader in rare diseases, Shire is committed to changing the course of the future for people with conditions such as chronic hypoparathyroidism

### REFERENCES

1. European Medicines Agency. Orphan designation. Available at: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general\\_content\\_000029.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp). Accessed April 2017.
2. Hadker N, Egan J, Sanders J, et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. *Endocr Pract.* 2014;20(7):671-9.
3. Powers J, Joy K, Ruscio A, et al. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. *J Bone Miner Res.* 2013;28(12):2570-6.
4. Underbjerg L, Sikjaer T, Mosekilde L, et al. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. *J Bone Miner Res.* 2013;28(11):2277-85.
5. Astor MC, Lovas K, Debowska A, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. *J Clin Endocrinol Metab.* 2016;101(8):3045-53.
6. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. *J Clin Endocrinol Metab.* 2012;97(12):4507-14.
7. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. *J Clin Endocrinol Metab.* 2016;101(6):2300-12.
8. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. *J Clin Endocrinol Metab.* 2016;101(6):2284-99.
9. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. *Eur J Endocrinol.* 2015;173(2):G1-20.
10. Underbjerg L, Sikjaer T, Mosekilde L, et al. The Epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. *J Bone Miner Res.* 2015;30(9):1738-44.
11. Brandt ML, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. *J Clin Endocrinol Metab.* 2016;101: 2273-2283.
12. Arlt et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. *Eur J Endocrinol.* 2002;146:215-22